Skip to main content
H

Hutchmed (China) Limited — Investor Relations & Filings

Ticker · HCM ISIN · KYG4672N1198 LEI · 2138006X34YDQ6OBYE79 HKEX Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2026-03-05 Annual Report
Country KY Cayman Islands
Listing HKEX HCM

About Hutchmed (China) Limited

https://www.hutch-med.com/

Hutchmed is a commercial-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapeutics and immunotherapies. The company operates a fully integrated platform, advancing a pipeline of novel drug candidates for the treatment of cancer and immunological diseases. Its research and development strategy focuses on creating highly selective and potent therapies engineered to improve drug exposure and reduce off-target toxicities. Hutchmed has multiple internally discovered medicines approved and marketed for various oncology and immunology indications, supported by a global commercialization infrastructure.

Recent filings

Filing Released Lang Actions
2025 Full Year Results and Business Updates
Annual Report
2026-03-05 English
HUTCHMED Initiates Global Trial of ATTC Candidate
Regulatory Filings Classification · 1% confidence The document is a press release issued by HUTCHMED announcing the initiation of a Phase I/IIa clinical trial for a new drug candidate (HMPL-A580). It is distributed via the RNS (Regulatory News Service) Reach platform. Since it is a corporate announcement regarding clinical trial progress and does not fit into specific financial reporting categories like 10-K or IR, and is not a standalone report publication announcement (it is the content itself), it falls under the general regulatory announcement category.
2026-03-04 English
HUTCHMED to Announce 2025 Final Results
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from Hutchmed (China) Limited regarding the upcoming release of their 2025 final results. It specifies the date and time of the future announcement and provides details on how to access the webcast. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2026-02-06 English
6-K
Foreign Filer Report
2026-01-14 English
Publication of Phase III Results in The Lancet
Regulatory Filings Classification · 1% confidence The document is a press release from HUTCHMED (China) Limited announcing the publication of Phase III clinical trial results (SACHI) in the medical journal 'The Lancet'. It provides details on the trial's efficacy, safety, and background information on the drugs involved (ORPATHYS and TAGRISSO). It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate announcement regarding research and development milestones. As it is a press release detailing clinical trial outcomes, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-01-14 English
6-K
Foreign Filer Report
2026-01-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.